JP2010520289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520289A5 JP2010520289A5 JP2009552757A JP2009552757A JP2010520289A5 JP 2010520289 A5 JP2010520289 A5 JP 2010520289A5 JP 2009552757 A JP2009552757 A JP 2009552757A JP 2009552757 A JP2009552757 A JP 2009552757A JP 2010520289 A5 JP2010520289 A5 JP 2010520289A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- item
- therapy
- rapamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000011510 cancer Diseases 0.000 claims description 71
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 55
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 44
- 229960002930 sirolimus Drugs 0.000 claims description 44
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 44
- 239000002105 nanoparticle Substances 0.000 claims description 32
- 239000002552 dosage form Substances 0.000 claims description 26
- 102000014914 Carrier Proteins Human genes 0.000 claims description 25
- 108010078791 Carrier Proteins Proteins 0.000 claims description 25
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 102000009027 Albumins Human genes 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- -1 duanorubicin Natural products 0.000 claims description 8
- 238000001794 hormone therapy Methods 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 238000010322 bone marrow transplantation Methods 0.000 claims description 3
- 238000000315 cryotherapy Methods 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000011476 stem cell transplantation Methods 0.000 claims description 3
- 238000002626 targeted therapy Methods 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- 102100021906 Cyclin-O Human genes 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229930183665 actinomycin Natural products 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960001338 colchicine Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229940120982 tarceva Drugs 0.000 claims description 2
- 229940099039 velcade Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102000038030 PI3Ks Human genes 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 claims 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical group CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 claims 1
- 229950010632 perifosine Drugs 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 48
- 208000037819 metastatic cancer Diseases 0.000 description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000007452 Plasmacytoma Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010065305 Cancer in remission Diseases 0.000 description 2
- 206010038111 Recurrent cancer Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 229940071846 neulasta Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90566907P | 2007-03-07 | 2007-03-07 | |
| US90576707P | 2007-03-07 | 2007-03-07 | |
| US90573507P | 2007-03-07 | 2007-03-07 | |
| US90566207P | 2007-03-07 | 2007-03-07 | |
| US90567207P | 2007-03-07 | 2007-03-07 | |
| US90575007P | 2007-03-07 | 2007-03-07 | |
| US90578707P | 2007-03-07 | 2007-03-07 | |
| US90566307P | 2007-03-07 | 2007-03-07 | |
| US90573407P | 2007-03-07 | 2007-03-07 | |
| US92324807P | 2007-04-13 | 2007-04-13 | |
| US92345607P | 2007-04-13 | 2007-04-13 | |
| PCT/US2008/003096 WO2008109163A1 (en) | 2007-03-07 | 2008-03-07 | Nanoparticle comprising rapamycin and albumin as anticancer agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013223132A Division JP6348698B2 (ja) | 2007-03-07 | 2013-10-28 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520289A JP2010520289A (ja) | 2010-06-10 |
| JP2010520289A5 true JP2010520289A5 (enExample) | 2011-04-28 |
Family
ID=39562000
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552757A Withdrawn JP2010520289A (ja) | 2007-03-07 | 2008-03-07 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2013223132A Active JP6348698B2 (ja) | 2007-03-07 | 2013-10-28 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2015202611A Withdrawn JP2016011309A (ja) | 2007-03-07 | 2015-10-14 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2017093894A Active JP6544812B2 (ja) | 2007-03-07 | 2017-05-10 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2018127659A Pending JP2018150381A (ja) | 2007-03-07 | 2018-07-04 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2019185794A Pending JP2020002177A (ja) | 2007-03-07 | 2019-10-09 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013223132A Active JP6348698B2 (ja) | 2007-03-07 | 2013-10-28 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2015202611A Withdrawn JP2016011309A (ja) | 2007-03-07 | 2015-10-14 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2017093894A Active JP6544812B2 (ja) | 2007-03-07 | 2017-05-10 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2018127659A Pending JP2018150381A (ja) | 2007-03-07 | 2018-07-04 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| JP2019185794A Pending JP2020002177A (ja) | 2007-03-07 | 2019-10-09 | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8911786B2 (enExample) |
| EP (4) | EP3417859A1 (enExample) |
| JP (6) | JP2010520289A (enExample) |
| KR (5) | KR101943230B1 (enExample) |
| CN (1) | CN104814930B (enExample) |
| AU (1) | AU2008223334B2 (enExample) |
| BR (1) | BRPI0808635B1 (enExample) |
| CA (3) | CA3201293A1 (enExample) |
| CY (3) | CY1120547T1 (enExample) |
| DK (3) | DK2481409T3 (enExample) |
| ES (3) | ES2690175T3 (enExample) |
| HR (3) | HRP20181159T1 (enExample) |
| HU (3) | HUE039643T2 (enExample) |
| IL (2) | IL200755A (enExample) |
| LT (3) | LT2481402T (enExample) |
| MX (2) | MX2009009537A (enExample) |
| NZ (2) | NZ711695A (enExample) |
| PL (3) | PL2481402T3 (enExample) |
| PT (3) | PT2481402T (enExample) |
| RU (3) | RU2483714C2 (enExample) |
| SI (3) | SI2481402T1 (enExample) |
| UA (1) | UA118645C2 (enExample) |
| WO (1) | WO2008109163A1 (enExample) |
| ZA (1) | ZA200906342B (enExample) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE042678T2 (hu) * | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| CA3201293A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2309991B1 (en) | 2008-06-16 | 2019-03-06 | Pfizer Inc | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| JP2012510442A (ja) * | 2008-11-28 | 2012-05-10 | ノバルティス アーゲー | Ｈｓｐ９０阻害剤の組合せ |
| EP2379064B1 (en) | 2008-12-15 | 2020-02-26 | Pfizer Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
| EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| EP2416792A4 (en) * | 2009-04-10 | 2012-10-24 | Haiyan Qi | NOVEL ANTI-AGING AGENTS AND METHODS OF IDENTIFICATION |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| WO2011072218A2 (en) | 2009-12-11 | 2011-06-16 | Bind Biosciences | Stable formulations for lyophilizing therapeutic particles |
| ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| GB2478556A (en) * | 2010-03-09 | 2011-09-14 | Myrovlytis Technology Ventures Ltd | A composition for use in the treatment of Birt-Hogg-Dubô sydrome |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| WO2012054564A2 (en) * | 2010-10-19 | 2012-04-26 | The Curators Of The University Of Missouri | Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods |
| US8691777B2 (en) | 2011-01-27 | 2014-04-08 | Emory University | Combination therapy |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9731012B2 (en) * | 2012-03-30 | 2017-08-15 | President And Fellows Of Harvard College | Laser-actuated therapeutic nanoparticles |
| WO2013188763A1 (en) * | 2012-06-15 | 2013-12-19 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| JP2015526471A (ja) * | 2012-08-21 | 2015-09-10 | ジェネシス リサーチ インスティチュート | アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法 |
| US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
| WO2014043625A1 (en) * | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9918968B2 (en) * | 2013-01-03 | 2018-03-20 | The Board Of Regents Of The University Of Texas System | Rapamycin analogs targeting proteasome function in the treatment of cancer |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| EP2968191B1 (en) * | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| EP2967059A4 (en) * | 2013-03-15 | 2017-03-22 | The Board of Regents of The University of Texas System | Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth |
| KR101329646B1 (ko) | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
| CA2910579C (en) * | 2013-05-03 | 2023-09-26 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| CA2910584A1 (en) * | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells |
| WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| ES2784423T3 (es) | 2013-09-16 | 2020-09-25 | Astrazeneca Ab | Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso |
| US20160271072A1 (en) * | 2013-10-22 | 2016-09-22 | The University Of North Carolina At Chapel Hill | Polymer nanoparticles containing multiple agents and methods thereof |
| CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| MX378984B (es) | 2014-03-14 | 2025-03-11 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso. |
| CA2950926A1 (en) | 2014-06-13 | 2015-12-17 | Mayo Foundation For Medical Education And Research | Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| WO2016172069A1 (en) * | 2015-04-20 | 2016-10-27 | Washington State University | Methods of treating inflammation associated airway diseases and viral infections |
| US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
| WO2016205334A1 (en) | 2015-06-16 | 2016-12-22 | Vascular Strategies Llc | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| MX2017016491A (es) * | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). |
| EA036790B1 (ru) * | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| HK1254398A1 (zh) * | 2015-06-29 | 2019-07-19 | Abraxis Bioscience, Llc | 納米粒子組合物的生物標誌物 |
| US20180153863A1 (en) * | 2015-06-29 | 2018-06-07 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| WO2017031368A1 (en) * | 2015-08-18 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US10765665B2 (en) | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
| US20220280233A1 (en) * | 2015-12-23 | 2022-09-08 | Theromics, Inc. | Devices, methods, and compositions for thermal acceleration and drug delivery |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| MX380313B (es) | 2016-02-04 | 2025-03-12 | Univ Johns Hopkins | Rapadocinas, inhibidores de transportador 1 de nucleósido equilibrador y usos de los mismos. |
| MX2018009408A (es) * | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| EP3417289B1 (en) | 2016-02-19 | 2020-12-23 | Nant Holdings IP, LLC | Methods of immunogenic modulation |
| JP2019510085A (ja) * | 2016-03-08 | 2019-04-11 | ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌治療のためのナノ粒子ならびに方法および化合物 |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| US10894960B2 (en) | 2016-08-30 | 2021-01-19 | Children's Hospital Medical Center | Compositions and methods for nucleic acid transfer |
| MX2019002474A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
| EA201990820A1 (ru) * | 2016-09-28 | 2019-10-31 | Способы лечения митохондриальных и метаболических нарушений | |
| ES2944576T3 (es) * | 2017-01-06 | 2023-06-22 | Santen Pharmaceutical Co Ltd | Administración intratumoral de sirólimus para el tratamiento del cáncer de próstata |
| JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US12411144B2 (en) | 2017-03-22 | 2025-09-09 | Children's Hospital Medical Center | Compositions and methods for treatment of lung function |
| US10806801B2 (en) | 2017-06-07 | 2020-10-20 | National Cheng Kung University | Pharmaceutical composition and methods for using the same |
| WO2019073371A1 (en) | 2017-10-11 | 2019-04-18 | Wockhardt Limited | PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-LIPID HYBRID NANOPARTICLES |
| US20190184031A1 (en) * | 2017-12-19 | 2019-06-20 | Abraxis Bioscience, Llc | Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy |
| AU2018389243A1 (en) * | 2017-12-21 | 2020-08-06 | The Angiogenesis Foundation | Compositions and methods for treating neoplasia |
| EP3755303A1 (en) * | 2018-02-23 | 2020-12-30 | Biotronik AG | Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures |
| EP3768268A4 (en) * | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| KR20210024471A (ko) | 2018-05-22 | 2021-03-05 | 아브락시스 바이오사이언스, 엘엘씨 | 폐고혈압을 치료하기 위한 방법 및 조성물 |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| CN120267635A (zh) * | 2019-03-19 | 2025-07-08 | 阿布拉科斯生物科学有限公司 | 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 |
| US20220257523A1 (en) * | 2019-07-16 | 2022-08-18 | The Regents Of The University Of Michigan | Composite drug particles and uses thereof |
| EP4051241A4 (en) * | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| MX2022005715A (es) * | 2019-11-11 | 2022-09-19 | Abraxis Bioscience Llc | Biomarcadores para composiciones de nanoparticulas. |
| KR102641217B1 (ko) * | 2019-12-24 | 2024-02-29 | (주)아이엠지티 | 항암제가 코팅된 알부민 나노입자 및 이의 제조방법 |
| KR102517033B1 (ko) | 2020-07-15 | 2023-04-03 | 성균관대학교산학협력단 | 엔도텔린 수용체 길항제를 봉입한 나노입자 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| JP2023552809A (ja) * | 2020-12-10 | 2023-12-19 | チルドレンズ ホスピタル メディカル センター | 増強されたナノ粒子送達システム |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
| WO2022226052A1 (en) * | 2021-04-20 | 2022-10-27 | The Regents Of The University Of Michigan | Pi3k inhibitors, nanoformulations, and uses thereof |
| KR102837034B1 (ko) | 2022-09-28 | 2025-07-22 | 충남대학교산학협력단 | 피로인산티아민 알부민 나노클러스터를 포함하는 항암치료용 조성물 및 이의 제조방법 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN116271067A (zh) * | 2023-03-20 | 2023-06-23 | 山东大学齐鲁医院 | 一种基于hsp90抑制剂白蛋白纳米药物及其制备方法与应用 |
| WO2024228964A1 (en) | 2023-04-30 | 2024-11-07 | Aadi Bioscience, Inc. | Treatments comprising an mtor inhibitor nanoparticle composition |
| WO2024243413A1 (en) * | 2023-05-24 | 2024-11-28 | Aadi Bioscience, Inc. | Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma |
| WO2025034870A1 (en) * | 2023-08-08 | 2025-02-13 | Aadi Bioscience, Inc. | Combination of nab-sirolimus and an estrogen suppresor for use in the treatment of hormone-dependent cancers |
| WO2025049962A1 (en) | 2023-08-31 | 2025-03-06 | Aadi Bioscience, Inc. | Combination cancer treatments with a composition comprising an mtor pathway inhibitor |
| WO2025129108A1 (en) | 2023-12-14 | 2025-06-19 | Aadi Bioscience, Inc. | Methods of treating a cancer in an individual |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5540931A (en) | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| PT693924E (pt) | 1993-02-22 | 2004-09-30 | American Biosciences | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070122465A1 (en) | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| EP1683517A1 (en) * | 1996-08-19 | 2006-07-26 | American Bioscience, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| CN100462066C (zh) | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| EP1178786A4 (en) | 1999-05-21 | 2006-03-01 | American Bioscience Inc | PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE |
| GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| PT2269603E (pt) * | 2001-02-19 | 2015-09-09 | Novartis Ag | Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano |
| PL363991A1 (en) | 2001-04-06 | 2004-11-29 | Wyeth | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
| BR0210101A (pt) * | 2001-06-01 | 2004-06-08 | Wyeth Corp | Combinações antineoplásticas |
| US20030054042A1 (en) | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| JP4212921B2 (ja) * | 2002-03-29 | 2009-01-21 | 独立行政法人科学技術振興機構 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
| CA2480809A1 (en) | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| NZ541142A (en) * | 2002-12-09 | 2008-07-31 | Abraxis Bioscience Inc | Compositions and methods of delivery of pharmacological agents |
| WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US20050038498A1 (en) | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
| US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| CN1980699B (zh) * | 2004-05-14 | 2012-03-21 | 阿布拉西斯生物科学公司 | 利用白蛋白-结合蛋白作为靶标的治疗方法 |
| KR20070012486A (ko) | 2004-05-17 | 2007-01-25 | 노파르티스 아게 | 유기 화합물의 조합 |
| WO2006039336A2 (en) * | 2004-10-01 | 2006-04-13 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| WO2006053754A1 (en) | 2004-11-19 | 2006-05-26 | Novartis Ag | COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| ES2663495T3 (es) | 2005-02-18 | 2018-04-13 | Abraxis Bioscience, Llc | Fármacos con hidrofobicidad mejorada para incorporación en dispositivos médicos |
| WO2006089292A2 (en) * | 2005-02-18 | 2006-08-24 | Abdou M S | Devices and methods for dynamic fixation of skeletal structure |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN101175481A (zh) | 2005-03-17 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米颗粒免疫抑制化合物的可注射的组合物 |
| DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
| US7514549B2 (en) * | 2005-04-16 | 2009-04-07 | Michigan State University | Tumor inhibition by modulating sprouty expression or activity |
| US20080214595A1 (en) | 2005-05-16 | 2008-09-04 | Seigo Izumo | Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
| MX2009002054A (es) | 2006-08-31 | 2009-05-01 | Abraxis Bioscience Llc | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| CA3201293A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| AU2009234127B2 (en) | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2367425B1 (en) | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
| WO2010105172A1 (en) | 2009-03-13 | 2010-09-16 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| BRPI1014160A2 (pt) | 2009-04-10 | 2015-08-25 | Abraxis Bioscience Llc | Formulações de nanopartículas e aplicações das mesmas |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| SG178873A1 (en) | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| US9775819B2 (en) | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| WO2011153009A1 (en) | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| EP2968191B1 (en) * | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
-
2008
- 2008-03-07 CA CA3201293A patent/CA3201293A1/en active Pending
- 2008-03-07 PL PL12152455T patent/PL2481402T3/pl unknown
- 2008-03-07 ES ES12152463.1T patent/ES2690175T3/es active Active
- 2008-03-07 KR KR1020177002049A patent/KR101943230B1/ko active Active
- 2008-03-07 PT PT12152455T patent/PT2481402T/pt unknown
- 2008-03-07 CN CN201510163181.4A patent/CN104814930B/zh active Active
- 2008-03-07 CA CA3006137A patent/CA3006137C/en active Active
- 2008-03-07 CA CA2680207A patent/CA2680207C/en active Active
- 2008-03-07 KR KR1020147033327A patent/KR20150002886A/ko not_active Ceased
- 2008-03-07 ES ES08726605.2T patent/ES2686150T3/es active Active
- 2008-03-07 KR KR1020197033753A patent/KR102154459B1/ko active Active
- 2008-03-07 HU HUE12152455A patent/HUE039643T2/hu unknown
- 2008-03-07 HR HRP20181159TT patent/HRP20181159T1/hr unknown
- 2008-03-07 EP EP18167003.5A patent/EP3417859A1/en active Pending
- 2008-03-07 SI SI200831985T patent/SI2481402T1/sl unknown
- 2008-03-07 MX MX2009009537A patent/MX2009009537A/es active IP Right Grant
- 2008-03-07 MX MX2015013895A patent/MX380318B/es unknown
- 2008-03-07 PT PT08726605T patent/PT2131821T/pt unknown
- 2008-03-07 SI SI200831982T patent/SI2481409T1/sl unknown
- 2008-03-07 DK DK12152463.1T patent/DK2481409T3/en active
- 2008-03-07 UA UAA201213559A patent/UA118645C2/uk unknown
- 2008-03-07 US US12/530,188 patent/US8911786B2/en active Active
- 2008-03-07 DK DK08726605.2T patent/DK2131821T3/en active
- 2008-03-07 EP EP12152455.7A patent/EP2481402B1/en active Active
- 2008-03-07 JP JP2009552757A patent/JP2010520289A/ja not_active Withdrawn
- 2008-03-07 RU RU2009136992/15A patent/RU2483714C2/ru active
- 2008-03-07 HU HUE12152463A patent/HUE039497T2/hu unknown
- 2008-03-07 KR KR1020197001911A patent/KR102047634B1/ko active Active
- 2008-03-07 AU AU2008223334A patent/AU2008223334B2/en active Active
- 2008-03-07 PT PT12152463T patent/PT2481409T/pt unknown
- 2008-03-07 BR BRPI0808635-4A patent/BRPI0808635B1/pt active IP Right Grant
- 2008-03-07 EP EP08726605.2A patent/EP2131821B1/en active Active
- 2008-03-07 LT LTEP12152455.7T patent/LT2481402T/lt unknown
- 2008-03-07 KR KR1020097020819A patent/KR20090118999A/ko not_active Ceased
- 2008-03-07 LT LTEP12152463.1T patent/LT2481409T/lt unknown
- 2008-03-07 LT LTEP08726605.2T patent/LT2131821T/lt unknown
- 2008-03-07 PL PL08726605T patent/PL2131821T3/pl unknown
- 2008-03-07 ES ES12152455.7T patent/ES2690174T3/es active Active
- 2008-03-07 PL PL12152463T patent/PL2481409T3/pl unknown
- 2008-03-07 NZ NZ711695A patent/NZ711695A/en unknown
- 2008-03-07 EP EP12152463.1A patent/EP2481409B1/en active Active
- 2008-03-07 SI SI200831980T patent/SI2131821T1/sl unknown
- 2008-03-07 DK DK12152455.7T patent/DK2481402T3/en active
- 2008-03-07 HU HUE08726605A patent/HUE038701T2/hu unknown
- 2008-03-07 WO PCT/US2008/003096 patent/WO2008109163A1/en not_active Ceased
- 2008-03-07 NZ NZ621972A patent/NZ621972A/en unknown
-
2009
- 2009-09-06 IL IL200755A patent/IL200755A/en active IP Right Grant
- 2009-09-11 ZA ZA2009/06342A patent/ZA200906342B/en unknown
-
2013
- 2013-02-27 US US13/779,621 patent/US20130280336A1/en not_active Abandoned
- 2013-03-04 RU RU2013109422A patent/RU2678448C2/ru active
- 2013-10-28 JP JP2013223132A patent/JP6348698B2/ja active Active
-
2014
- 2014-10-28 US US14/526,358 patent/US20150050356A1/en not_active Abandoned
-
2015
- 2015-10-14 JP JP2015202611A patent/JP2016011309A/ja not_active Withdrawn
-
2017
- 2017-02-05 IL IL250445A patent/IL250445A0/en unknown
- 2017-05-10 JP JP2017093894A patent/JP6544812B2/ja active Active
-
2018
- 2018-07-04 JP JP2018127659A patent/JP2018150381A/ja active Pending
- 2018-07-27 HR HRP20181198TT patent/HRP20181198T1/hr unknown
- 2018-07-30 HR HRP20181217TT patent/HRP20181217T1/hr unknown
- 2018-08-08 CY CY20181100824T patent/CY1120547T1/el unknown
- 2018-08-08 CY CY20181100826T patent/CY1120555T1/el unknown
- 2018-08-08 CY CY20181100825T patent/CY1120548T1/el unknown
- 2018-09-24 US US16/140,339 patent/US20190022020A1/en not_active Abandoned
-
2019
- 2019-01-22 RU RU2019101632A patent/RU2019101632A/ru not_active Application Discontinuation
- 2019-10-09 JP JP2019185794A patent/JP2020002177A/ja active Pending
-
2021
- 2021-02-24 US US17/184,506 patent/US20210322335A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,775 patent/US20240065984A1/en not_active Abandoned
-
2024
- 2024-11-19 US US18/952,634 patent/US20250186359A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520289A5 (enExample) | ||
| ES2374828T3 (es) | Combinaciones de agentes terapéuticos para el tratamiento del cáncer. | |
| Carter et al. | Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma | |
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| RU2009136992A (ru) | Наночастица, содержащая рапамиции и альбумин, в качестве противоракового агента | |
| JP2011511071A (ja) | 肺癌を治療するためのピコプラチンおよびアムルビシン | |
| JP2008530248A5 (enExample) | ||
| RU2007134571A (ru) | Комбинация и способы введения терапевтических средств и комбинированной терапии | |
| US20220265592A1 (en) | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer | |
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| CN104083365A (zh) | 癌症的治疗 | |
| CN103282037A (zh) | 抗肿瘤生物碱的联合治疗 | |
| JP7372253B2 (ja) | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| Huang et al. | Pemetrexed as a component of first-, second-and third-line chemotherapy in treating patients with metastatic lung adenocarcinoma | |
| JP2021505548A (ja) | 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用 | |
| CN1674908A (zh) | erb B激酶抑制剂和抗肿瘤疗法的联合治疗 | |
| JP2007277240A5 (enExample) | ||
| A Boere et al. | Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer | |
| TWI752147B (zh) | [6r]-亞甲基四氫葉酸-在基於5-氟尿嘧啶的化療中有效的葉酸替代物 | |
| JP2016505043A5 (enExample) | ||
| Sun et al. | Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells | |
| CN111643502A (zh) | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 | |
| CN114173785B (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 |